Eli Lilly launches Mounjaro weight-loss drug in India

Eli Lilly has officially launched its weight-loss and diabetes drug, Mounjaro, in India after getting clearance from the country's drug regulator. This launch comes at a time when obesity and diabetes rates are on the rise in India, creating a strong market for the medication. Mounjaro, known as tirzepatide, is already available in other countries like the UK and Europe. In the U.S., it is marketed under the name Zepbound specifically for obesity treatment. Eli Lilly sees India as a significant opportunity since the country has approximately 101 million people living with diabetes. Winselow Tucker, Eli Lilly's President and General Manager in India, highlighted the growing public health challenge of obesity and type 2 diabetes in the region. As these conditions become more common, the demand for effective treatments like Mounjaro is expected to increase. CEO David Ricks mentioned that the company aimed to launch the drug in India by 2025. Analysts project that global sales of obesity drugs could reach $150 billion annually by the early 2030s, indicating strong future growth in this market.